(BGM) Qilian International - Ratings and Ratios

BGM Group Ltd is a Chinese pharmaceutical company that specializes in the manufacture and distribution of active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other related products. The companys product portfolio includes licorice extracts, oxytetracycline tablets and APIs, heparin products, and other TCMDs, which cater to various industries such as pharmaceuticals, animal health, and food production.

The companys licorice products, such as Gan Di Xin and Qilian Shan Licorice Extract, are used in the production of antitussive and expectorant medicines, as well as traditional licorice tablets. Additionally, BGM Group Ltd offers oxytetracycline tablets and APIs for use in veterinary medicine and human health. The companys TCMD products, including Ahan antibacterial paste, are designed to treat various health conditions, while its heparin products are used in the treatment of cardiovascular and cerebrovascular diseases.

Beyond its pharmaceutical and TCMD offerings, BGM Group Ltd also produces organic and inorganic fertilizers, such as Xiongguan organic fertilizers, which aim to improve crop yields and soil quality. The companys diverse product range and industry applications position it for potential growth in various markets.

Analyzing the , we observe that BGMs stock price has been trending upwards, with the short-term and long-term moving averages (SMA20: 11.41, SMA50: 10.89, SMA200: 8.83) indicating a positive momentum. The Average True Range (ATR: 0.69 = 5.60%) suggests moderate volatility. Given the current price (12.35) is near the 52-week high (13.00), we can anticipate potential resistance at this level. Considering the , the companys Market Cap (46.83M USD) and negative RoE (-3.17) may raise concerns about its profitability. However, the absence of P/E and P/E Forward values may indicate that the company is not yet profitable or is in a growth phase.

Based on the available data, a forecast for BGM Group Ltd could be that the stock price may continue to rise in the short term, driven by its positive technical indicators. However, the companys fundamental data raises concerns about its profitability, which may impact its long-term growth prospects. To mitigate potential risks, investors may consider monitoring the companys future earnings reports and industry trends. A potential target price could be around 15.00, based on a combination of technical analysis and fundamental insights. Nevertheless, this forecast is subject to significant uncertainty and should be treated with caution.